Indianapolis-based Eli Lilly & Co. and its Japanese partner are seeking to reassure investors that a highly anticipated blood thinner remains on track for approval, despite escalating concerns of further delays by federal health regulators.

Wall Street has big hopes for the potential blockbuster medication, called prasugrel (PRA'-suh-grel). But in late September, the Food and Drug Administration postponed its decision on the drug for a second time.

In a joint statement, Lilly and Daiichi Sankyo say they have not been contacted regarding any regulatory action or advisory committee review of the drug.

Prasugrel is designed to treat patients with acute heart problems such as heart attacks or unstable angina who are at risk of developing blood clots.